What did the ERG conclude about how the heterogeneity of the comparison arm affected the synthesis of results (for the same node in the network)?
In the ERG's view, did the distribution of study outcomes justify the type of NMA conducted? Did the ERG consider the level of heterogeneity acceptable enough for the NMA to be regarded as valid?
*NICE Guide to the methods of technology appraisal 2013 and guidance published by NICE Decision Support Unit (http://www.nicedsu.org.uk/ Evidence-Synthesis-TSD-series(2391675).htm). 
Manufacturer's submission
Mixed-population studies (most commonly reflecting different disease stages/severity) were included.
This was noted in submissions as a potential source of heterogeneity due to different treatments acting as "usual care" including placebo.
Typically, the selection of the different types of NMA was not clearly justified.
This was most commonly explored by Cochrane's Q or I2 tests and subgroup analyses or presented narratively.
ERG critique
The manufacturers' approach was often criticised because of the lack of further analysis of the effect of using different mixed-population thresholds for deciding whether such studies should be included.
ERGs noted that where the groups composing the comparison arm differed with regards to baseline risks, no sensitivity analysis was performed to explore the potential effects of these differences.
ERGs noted that distributional assumptions were not always tested before the selection of the NMA type to be used in the submission.
Manufacturers were often criticised for not fully exploring heterogeneity in the NMA by conducting subgroup analyses. In some cases, manufacturers were criticised for conducting an NMA without accompanying exploration of heterogeneity in further analyses. In a few cases, the ERG agreed with manufacturer's opinion that studies were too heterogeneous to be synthesised in an NMA. 
OBJECTIVES
We aimed to investigate how, in the absence of explicit NICE guidance, manufacturers addressed the following key methodological issues in their TA submissions, and how these approaches were received by ERGs: -Heterogeneity in the SLR and NMA -Selection of the appropriate type of NMA To do this, we explored the following research questions: -If the SLR or NMA included mixed-population studies (i.e., those in which target patients for the index product were only a subgroup), how this was explored in the interpretation of evidence and what did the ERGs consider an acceptable threshold proportion of target patients for such studies to be included? -How comparable were the control groups across the included studies in the SLR or NMA? In the ERG's view, could this comparability relate to substantive differences between baseline risks across the control groups of the studies? -How heterogeneity was measured in the SLR or NMA and was this approach approved by the ERGs?
All decisions made by the National Institute for Health and Care Excellence (NICE) regarding new drugs exert an influence on the allocation of fixed resources in the National Health Service in the United Kingdom. It is therefore crucial that the information supplied in reimbursement submissions is of sufficiently high quality and that the requirements to meet this standard are transparent. In reality, however, manufacturers preparing technology appraisal (TA) submissions often face a lack of explicit direction -in NICE's publicly available methods guidance -on, for example, key aspects of conducting a systematic literature review (SLR) and network meta-analysis (NMA) to generate comparative data for their products. We therefore explored evidence review group (ERG) critiques of SLRs and NMAs included in manufacturers' TA submissions to see whether or not they suggest NICE has expectations or preferences for how such research should be done, beyond those stated in its guidance for manufactureres.
RESULTS

CONCLUSIONS
Recurring ERG criticisms of SLR and NMA methodology in TA submissions suggest that although there is no, or only, partially explicit NICE guidance on specific heterogeneity and NMA considerations, the ERGs seem to have clear rules on how evidence should be synthesised in the SLR and analysed in the NMA. It is important that the way NICE evaluates evidence underpinning TAs submissions is consistent and reflects clearly articulated and publicly available methods guidance. With this in mind, clear advice about assessing heterogeneity and use of mixed-population studies for evidence synthesis in TAs is urgently needed. In the absence of such information, the following are sensible precautions when conducting an SLR and/or NMA for NICE TA submissions, based on common ERG criticisms: -Use of mixed-population studies by applying rigorous thresholds for the proportion of target patients (e.g., over 67% or 90%) that have been frequently employed by NICE in other setttings (such as its Clinical Guidelines) -Clear specification of the sources of heterogeneity -Use of a random-effects model if heterogeneity is present -Use of subgroup analysis and meta-regression -Use of sensitivity analysis to test the validity of the main NMA results -Exploration of the direction of relative effects across different baseline risks -Exploration of inconsistencies between direct and indirect evidence. If present, attempts should be made to explain and resolve such inconsistencies Data were extracted systematically from documents relating to 22 single TA submissions published on the NICE website between January to June 2016, most of which were related to oncology products. Four manufacturers' TA submissions included only results from single trials, so ruling out any NMA, and these were not considered further in our study. The thematic analysis of information for the remaining TAs (Table 2) indicated that heterogeneity associated with mixed-population trials was a key issue and was commonly noted by the ERGs to be due to differences in disease stages/severity between these studies. Manufacturers' NMA submissions were most often criticised for neither adequately assessing such heterogeneity nor exploring it through subgroup analyses. Also, while manufacturers acknowledged that the proportional-hazard assumption (i.e. that hazard ratios for a given outcome remain constant over time) was often not met in their analyses, they had generally taken no steps to control for this in their statistical analysis plans, and this omission was criticised universally by the ERGs.
Of note, the NICE Guide to the methods of technology appraisal 2013 (the NICE Guide) provides no clear guidance on what proportions of target patients there should be in mixed-population studies to make these eligible for inclusion in NMAs, nor on the acceptable level of heterogeneity within such analyses. The NICE Guide does provide guidance on dealing with non-proportional hazards but this was not always followed in TA manufacturer submissions.
METHODS
All single TA submissions published between January and June 2016 were identified from NICE's website (www.nice.org.uk). Subsequently, one researcher extracted information from each submission and related ERG critique on various aspects of the SLR and NMA as detailed in Table 1 . All extractions were validated by a second researcher and any discrepancies were resolved by a third senior researcher. Thematic analysis of the extracted information and publicly available methodological advice from NICE was then conducted.
